• london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Reading: Novo Nordisk announces key executive management changes effective April 2025
Share
Notification
  • london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Have an existing account? Sign In
MedEdge MEA > Resource Hub > Personnel > Novo Nordisk announces key executive management changes effective April 2025
Personnel

Novo Nordisk announces key executive management changes effective April 2025

ME Desk
ME Desk
Published: April 12, 2025
Share
2 Min Read
Novo Nordisk 1
SHARE

Bagsværd, Denmark- April 2025– Novo Nordisk announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company. Consequently, as of 3 April 2025, the following organisational changes are implemented:

Ludovic Helfgott, executive vice president, Rare Disease, will assume the responsibility for Product & Portfolio Strategy, including commercial strategy, medical affairs and business development across all therapy areas. Ludovic joined Novo Nordisk in 2019 as executive vice president and has led the establishment of a strategic Rare Disease portfolio. Before joining Novo Nordisk, Ludovic was responsible for the cardiovascular, metabolic and renal portfolios at AstraZeneca.

Thilde Hummel Bøgebjerg, senior vice president, Product Supply Emerging Technologies, is promoted to executive vice president, Quality, IT & Environmental Affairs. Thilde has been with Novo Nordisk for 18 years and has held various leadership roles with increasing responsibility, mainly within Product Supply and CMC development. Thilde is a Danish national based in Denmark.

Also Read : CagriSema shows promise in Novo Nordisk’s phase 3 obesity trial

Lastly, Tania Sabroe, executive vice president of People & Organisation, assumes responsibility for Global Communication in addition to her current responsibilities.

With these changes, Executive Management will have the following members as of 3 April 2025:

  • Lars Fruergaard Jørgensen, president and CEO*
  • Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs
  • Maziar Mike Doustdar, EVP, International Operations
  • Ludovic Helfgott, EVP, Product & Portfolio Strategy
  • Karsten Munk Knudsen, EVP, chief financial officer*
  • Martin Holst Lange, EVP, Development
  • Dave Moore, EVP, US Operations
  • Tania Sabroe, EVP, People, Organisation and Communication
  • Marcus Schindler, EVP, chief scientific officer, Research & Early Development
  • Henrik Wulff, EVP, Product Supply

* Registered as an executive with the Danish Business Authority.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article immune system Boost immune system: Stay strong with five foods that enhance your immunity.
Next Article RINVOQ European Commission approves AbbVie’s RINVOQ® for treatment of Giant Cell Arteritis

Recent Posts

  • NMSS AND ERTH ZAYED PHILANTHROPIES SIGN AED 25 MILLION GRANT AGREEMENT TO MARK WORLD MS DAY
  • Liver Transplantation Enters the Era of Precision Diagnostics
  • Merck Gulf & Ovasave Host Women’s Health Forum in UAE
  • Inside Cleveland Clinic Abu Dhabi’s Heart Institute with Dr. Gopal Bhatnagar
  • Global Health Collaboration in Focus: Malek El Husseini at Abu Dhabi Global Health Week 2025
  • Dermatology expo rome
  • LifeSpin
  • Health ExpoIraq
  • Agora
Two Point Five Logo white
  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: Novo Nordisk announces key executive management changes effective April 2025
Share

Published by Two Point Five Media FZCO

  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: Novo Nordisk announces key executive management changes effective April 2025
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp
Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?